TY - JOUR
T1 - Selective laser trabeculoplasty in steroid-induced and uveitic glaucoma
AU - Zhou, Yujia
AU - Pruet, Christopher M.
AU - Fang, Chengbo
AU - Khanna, Cheryl L.
N1 - Funding Information:
Supported by: Mayo Foundation, Rochester, Minn. The sponsor or funding organization had no role in the design or conduct of this research.
Publisher Copyright:
© 2021
PY - 2022/8
Y1 - 2022/8
N2 - Objective: To compare primary selective laser trabeculoplasty (SLT) response in uveitic, steroid-induced, primary open-angle glaucoma (POAG) and pseudoexfoliative glaucoma (PEX). Design: Single-centre retrospective case–control study. Participants: Patients with uveitic glaucoma, steroid-induced glaucoma, POAG, or PEX who had their first SLT. Methods: Eyes with POAG or PEX were in control groups. Eyes with steroid-induced or uveitic glaucoma were in experimental groups. Change in intraocular pressure from baseline, treatment failure, complication rates, and medication use were compared using rank-sum and log-rank tests. Results: Six-hundred and eight eyes of 433 patients were enrolled. Steroid-induced glaucoma eyes had higher mean baseline pressure and a decrease in pressure at 3–8 weeks (27.6–17.4 mm Hg) than those with PEX (21.7–16.5 mm Hg; p < 0.001) or POAG (18.6–14.9 mm Hg; p ≤ 0.025). Failure rates after 2 years were lower in steroid-induced glaucoma (54%) than in PEX (84%; p = 0.01) or POAG (84%; p = 0.005). This survival benefit persisted when excluding patients with changes to their steroid dosing (p ≤ 0.03) but showed mixed results when compared with patients with a baseline pressure of 25mm Hg or greater (p = 0.020 vs PEX; p = 0.67 vs POAG). At 18 months, the steroid-induced group decreased ocular hypotensive medication use (3.5–1.9; p = 0.005); the uveitic group increased medication use (2.7–3.5; p = 0.02). Conclusions: SLT is an effective treatment for steroid-induced glaucoma, with greater response and a lower failure rate than in PEX and primary POAG, although high baseline intraocular pressure may be a confounder. Judicious use of SLT can be considered in uveitic glaucoma.
AB - Objective: To compare primary selective laser trabeculoplasty (SLT) response in uveitic, steroid-induced, primary open-angle glaucoma (POAG) and pseudoexfoliative glaucoma (PEX). Design: Single-centre retrospective case–control study. Participants: Patients with uveitic glaucoma, steroid-induced glaucoma, POAG, or PEX who had their first SLT. Methods: Eyes with POAG or PEX were in control groups. Eyes with steroid-induced or uveitic glaucoma were in experimental groups. Change in intraocular pressure from baseline, treatment failure, complication rates, and medication use were compared using rank-sum and log-rank tests. Results: Six-hundred and eight eyes of 433 patients were enrolled. Steroid-induced glaucoma eyes had higher mean baseline pressure and a decrease in pressure at 3–8 weeks (27.6–17.4 mm Hg) than those with PEX (21.7–16.5 mm Hg; p < 0.001) or POAG (18.6–14.9 mm Hg; p ≤ 0.025). Failure rates after 2 years were lower in steroid-induced glaucoma (54%) than in PEX (84%; p = 0.01) or POAG (84%; p = 0.005). This survival benefit persisted when excluding patients with changes to their steroid dosing (p ≤ 0.03) but showed mixed results when compared with patients with a baseline pressure of 25mm Hg or greater (p = 0.020 vs PEX; p = 0.67 vs POAG). At 18 months, the steroid-induced group decreased ocular hypotensive medication use (3.5–1.9; p = 0.005); the uveitic group increased medication use (2.7–3.5; p = 0.02). Conclusions: SLT is an effective treatment for steroid-induced glaucoma, with greater response and a lower failure rate than in PEX and primary POAG, although high baseline intraocular pressure may be a confounder. Judicious use of SLT can be considered in uveitic glaucoma.
UR - http://www.scopus.com/inward/record.url?scp=85115000709&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115000709&partnerID=8YFLogxK
U2 - 10.1016/j.jcjo.2021.05.006
DO - 10.1016/j.jcjo.2021.05.006
M3 - Article
C2 - 34119463
AN - SCOPUS:85115000709
SN - 0008-4182
VL - 57
SP - 277
EP - 283
JO - Canadian Journal of Ophthalmology
JF - Canadian Journal of Ophthalmology
IS - 4
ER -